CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this ...

As part of Arvinas global collaboration with Pfizer, the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy cli ...

Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data ...

Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.Golden, CO, Feb. 10, 2025 (GLOBE ...

The selective oral CDK4/6 inhibitor lerociclib (GB491) combined with fulvestrant (Faslodex) provided superior progression-free survival (PFS) and tolerability in patients with hormone receptor ...

The clinical trial, known as the CDK4/6 Inhibitor Dosing Knowledge Study, is investigating personalized dosing strategies for ...

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...